E/M Coding Alert - 2005 Issue 25
Pharmaceuticals: Medicare May Cut Ad Costs Out Of Drug Prices
Subscribe or sign in to view the full article.
Article Overview
This article discusses a bipartisan congressional proposal focused on prescription-drug advertising and its potential effect on Medicare and Medicaid drug purchasing costs. It is relevant to professionals who follow healthcare policy, pharmaceutical reimbursement, and public program spending because it outlines the legislative goal, the broader policy rationale, and the government programs affected.
Why This Topic Matters
Readers tracking Medicare, Medicaid, and pharmaceutical pricing policy may want to know about proposed changes that could affect how drug costs are allocated in public reimbursement settings.
What You Will Learn
- The policy issue involving direct-to-consumer pharmaceutical advertising and public program drug costs.
- The legislative proposal being discussed and the federal programs it would affect.
- The broader reimbursement and purchasing implications for Medicare and Medicaid.
- The roles of congressional sponsors and the policy rationale behind the proposal.
Who Should Read This
- Medical coders
- Billing professionals
- Revenue cycle staff
- Healthcare compliance professionals
- Practice administrators
- Pharmacy and pharmaceutical policy analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com